BioCurity Pharmaceuticals Inc.

Because we believe that fighting cancer is hard enough!

BioCurity Pharmaceuticals Inc.

Because we believe that fighting cancer is hard enough!

Jupiter, FL
Biotechnology
BioCurity is a biopharmaceutical company developing drugs to transform radiation therapy. Our mission is to prevent certain side effects of radiation therapy for cancer patients. The side effects range from burns to the skin for breast cancer patients to pneumonia for lung cancer patients. Damage to healthy tissue of cancer patients undergoing radiation therapy is a direct cause of these side effects. The proposed drugs under development are from BioCurity’s patented technology and have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. Consistent with our preclinical studies we intend to mitigate side effects of radiation therapy without impairing the effectiveness of radiation treatment.

$94,949

raised
100
Investors
$36.3M
Valuation
$4.25
Price per Share
$510.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$600K
Offering Max
Reg CF
Offering

$94,949

raised
100
Investors
$36.3M
Valuation
$4.25
Price per Share
$510.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$600K
Offering Max
Reg CF
Offering

Bonus Rewards

Get rewarded for investing more into BioCurity Pharmaceuticals Inc.

$510+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Reasons to Invest

Our proposed drugs are intended to provide cost effective protection for millions of cancer patients undergoing radiation therapy every year from the side effects of radiation therapy
Seven issued US patents with fully paid license for its technology in the US as well as international patents owned by the Company for our technology when patients are undergoing radiation combined with chemotherapy
BioCurity management is focused on meeting development milestones of the proposed drug (including a growing IP portfolio) and thereby increasing the valuation of BioCurity for investors with funds that are raised

Approximately 150 investors participated in BioCurity’s prior Crowdfunding offering. With a minimum investment of $510 you can become part of the solution to prevent radiation side effects. Discussions and due diligence are ongoing with quality healthcare strategic partners and institutional funds.

Collectively, we can make progress in developing drugs to transform radiation therapy.

Learn more about BioCurity

"Because we believe that fighting cancer is hard enough"

Radiation therapy is a common cancer treatment that can have serious side effects

Did you know that radiation therapy, just like chemotherapy, can cause harmful and medically detrimental side effects for patients with cancer?


Drugs that reduce side effects of chemotherapy have been developed by major pharmaceutical companies such as Amgen and GlaxoSmithKline.   A supportive care drug to mitigate the side effects caused by radiation therapy for cancer patients is long overdue. It could transform essential radiation treatment for cancer patients into a more tolerable therapy with fewer long-term negative consequences.


Complications and side effects of radiation therapy we seek to reduce include :

1. Ryan, Julie. “Ionizing Radiation: The Good, the Bad, and the Ugly”. J Invest Dermatol. 132 (2012): 985-993

2. Bray, Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206

3. Radvansky, Lauren, et al. “Prevention and Management of Radiation-Induced Dermatitis, Mucositis and Xerostomia.” Am J Health Syst Pharm. 12 (2013): 1025-1032

4. Peach, Matthew, et al. “Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.” Prostate Cancer. 15 (2015): 1-11

BioCurity is looking to move forward in developing its proposed drugs and positively impact the cancer treatment process for millions of patients worldwide.


Imagine…if cancer patients no longer had to worry about whether or not they were going to suffer from their radiation treatment

There is an unmet patient need to prevent or mitigate the side effects of life-saving radiation therapy

The lack of adequate treatment options available to prevent or mitigate the damage to normal tissue causes an unmet global need for millions of cancer patients. In 2018, $3 Billion in the United States alone was billed by hospitals for in-patient medical care costs to treat medical complications caused by radiation therapy - and this does not include the emotional costs endured by the cancer patients and their families. With topical tissue damage, scarring of breasts, or disfigurement of the head and neck area, cancer radiation leaves patients with permanent damage. 


We believe the use of BioCurity’s technology would save billions of dollars a year spent for inpatient treatment of radiation therapy side effects by eliminating the need for hospital stays globally.


Preclinical studies completed and third-party experts see promise

Radiation treatment for cancer patients causes damage to cell DNA and normal cells die. This death of normal cell causes the side effects. The driver in the cell death is the free radicals that are created by the radiation.

How it works

Eliminating Free radicals

BioCurity’s proprietary technology is intended to eliminate these free radicals, protecting the skin and healthy internal tissues from unwanted DNA damage and the ensuing side effects- without interfering with the treatment of cancer cells. Our first proposed drug is a topical for radiation dermatitis and with the support from a biotech venture or as part of a joint venture with a pharma company, we believe we would meet our goal to develop our proposed IV drug for the prevention of internal tissue radiation damage.

Source, Source, Source, Source, SourceSource

Why our drug is needed now more than ever

Healthcare services globally are in a limited supply and that has been demonstrated in today’s fight against the COVID pandemic. There is no better time to develop drugs that can reduce patient services including in-hospital stays and save billions of healthcare dollars annually. Cancer treatments and radiation therapy are not elective procedures and continue irrespective of the other demands on hospitals and healthcare services.

Every patient with cancer undergoing radiation therapy

Globally, approximately 6 million out of the approximate 18 million newly diagnosed cancer patients receive radiation therapy annually and 1 million of them live in the United States. BioCurity’s proposed drugs have the potential to significantly reduce radiation side effects for a plurality of these patients. Cancer survivors treated with radiation therapy for pain management, recurring or secondary cancers are also projected to benefit from our drug products.

The global radiation therapy market was valued at $5 Billion in the year 2019 and is expected to reach $10 Billion by year 2025 with the Asia-Pacific region the fastest growing regional market. The global radiation therapy market forecasts are primarily supported by the increasing incidence of cancer and related mortality globally and a higher demand and increasing adoption of radiation therapy for the treatment of various types of cancers.

Source

The first target market we intend to test with our topical drug is breast cancer patients. It is expected to provide a material decrease in government and insurance funds required to treat skin damage of burns, scars, and blisters:


  • Breast cancer is leading cancer in the United States for women, and it is estimated that 1 in 8 women in the United States will develop breast cancer over their lifetime.
  • Radiation treatment for breast cancer can be used after lumpectomy, after mastectomy, for pain management, for managing metastatic breast cancer and for treating locally advanced breast cancer.
  • Some form of skin damage has been referenced in the scientific literature to inflict nearly all women with breast cancer who are receiving radiation therapy.
  • The short term and long term skin damage associated with radiation therapy for breast cancer patients include localized burning and blisters that can often be permanent, open wounds, extreme swelling and tenderness of the breast and surrounding lymph nodes, and permanent scars.


Increasing the attractiveness to capital markets

With a fully paid license for its technology that is freely transferable and growing International patent portfolio, BioCurity is well situated for collaborative transactions with pharmaceutical strategic groups. We work with a lean team of professionals compared to many Biotech companies. Consultants are utilized to reduce the burn rate during this growth process. We anticipate as the market in biotech typically demonstrates, valuation increases as the product progresses through clinical development as the safety and efficacy data would have significant appeal to other pharmaceutical companies.  Favorable exit strategies for biotech companies include proceeding with clinical development up through a demonstration of clinical efficacy and then licensing the product or soliciting an acquisition.

Management has made efforts to structure the company with multiple exit strategies along the path of growth, to enable it to consider opportunities at any point along its growth curve.  BioCurity has audited financial statements to be transaction ready with a full corporate diligence room.

Striving to be an effective and FDA approved drug for the prevention of radiation dermatitis

BioCurity and its drug development and clinical consultants, believe its proposed topical drug is reasonable to manufacture, and if proven safe and effective can be marketed efficiently, and may be reimbursable as a supportive care product. The currently available treatments used to manage side effects from radiation have limited effectiveness and a large number of potential cancer patients represent a significant and global unmet need and tremendous value proposition for BioCurity’s proposed topical drug and other potential drugs such as the IV formulation for the protection of internal tissues.

IAEA Report 2017, Radiotherapy in Cancer Care, Facing the Global Challenge.

Improving the quality of life for cancer patients and survivors undergoing radiation therapy worldwide

Over the next three years, given adequate funding, we will be working to clinically develop our topical product for breast cancer patients. We intend to build out a management team, engage in-house consultants from the drug industry and execute the product development activities required to submit the Investigational New Drug Application for a breast cancer product.


While our immediate focus is developing a new investigational topical product for breast cancer radiation therapy, we have greater aspirations. With the establishment of efficacy for breast cancer then additional clinical trials with our topical product for other cancers could begin. Eventually, with a joint venture with a pharma company or support from a biotech venture fund, we aim to develop an IV formulation of our product designed to protect the internal tissue from radiation.

A strong management team and roster of advisors

BioCurity’s team is balanced by decades of experience in science, international business operations, and legal/banking experience.


Dr. Cheryl Baker Ph.D., the scientific founder, performed the preclinical development and testing alongside radiation oncologists, medical oncologists, and others in the medical community. She has published more than 45 peer-reviewed manuscripts, book chapters, and articles. 


Chairman of the Board, Sam Merchant, brings expertise in structuring and negotiating transactions globally in Biotechnology, Pharmaceutical R&D in the production, manufacturing, and distribution of products provides value-added for BioCurity’s overall clinical development goals. 


Executive board member Nancy Cass, Esq, uses her depth of knowledge in transactional and securities law to make certain BioCurity is transaction-ready and the due diligence and corporate governance is properly performed and managed. 


BioCurity is also guided by a group of expert third-party advisors with substantial experience in all phases of drug development and the biotech industry - they are our very dedicated Consultants and Advisors - MDs, PhDs, MBAs, with decades of Biotech experience.

Join us in transforming radiation therapy for cancer patients

BioCurity is sharing its story and reaching the non-accredited investors who can now become a part of BioCurity’s investment family. With adequate funding, we can continue to develop BioCurity’s drugs and meet the demand for a product that can transform the radiation therapy experience by limiting radiation therapy side effects. 


There is a pent-up demand for a supportive care product to transform and improve outcomes for cancer patients undergoing radiation therapy by reducing and preventing side effects. BioCurity’s goal is to have available its product to support all cancer patients undergoing radiation therapy and develop a drug to  improve the quality of life as a cancer patient and cancer survivor.  

Offering Summary


Company

:

BioCurity Pharmaceuticals Inc.

Corporate Address

:

110 Front Street, Suite 300, Jupiter, FL 33477

Offering Minimum

:

$9,996.00

Offering Maximum

:

$599,998.00

Minimum Investment Amount

(per investor)

:

$510.00











Terms


Offering Type

:

Equity

Security Name

:

Series 2 CF Convertible Preferred Stock

Minimum Number of Shares Offered

:

2,352

Maximum Number of Shares Offered

:

141,176

Price per Share

:

$4.25

Pre-Money Valuation

:

$36,320,126.00











Perks:

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below

The 10% Bonus for StartEngine Shareholders

BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series 2 CF Convertible Preferred Stock at $4.25 / share, you will receive 110 Series 2 CF Convertible Preferred Stock, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$222,611.00 USD
$342,484.00 USD
Cash And Cash Equivalents
$62,215.00 USD
$167,281.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$1,524,330.00 USD
$780,203.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$2,191,060.00 USD
-$1,570,893.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Funds Disbursement

11 days ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the BioCurity Pharmaceuticals Inc. offering. Here's an excerpt describing the specifics of the change:


BioCurity Pharmaceuticals Inc extended their campaign 60 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

BioCurity Press Release

about 2 months ago

BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy 


JUPITER, Fla., October 2, 2020 /PRNewswire/ -- BioCurity, a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients and survivors, received an issuance from the European Patent Office for BioCurity's EP patent #3169312 entitled "Treatment of Cancer with a Combination of Radiation, Cerium Oxide Nanoparticles, and a Chemotherapeutic Agent." This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in China, Russia*, Japan*, and Europe.


"BioCurity is focused on expanding its patent portfolio and has not ruled out developing additional preclinical data in cancer models such as breast and head & neck using a combination of radiation and chemotherapy to support pending international divisional patents. Having international patents positions BioCurity as a global leader in drug development using cerium oxide nanoparticles to mitigate radiation side effects," said Dr. Cheryl Baker, PhD. Scientific Co-Founder of BioCurity.


Short and long-term side effects from radiation therapy can impair a cancer patient’s medical treatment plan and can leave cancer survivors with permanent adverse conditions. “There is an estimated 3-billion-dollar healthcare cost for in-patient treatment of medical side effects from radiation therapy in the US annually. The unmet need is well documented,” said Dr. Baker, PhD. The global cancer supportive care market is poised to reach approximately 22 billion dollars by 2026.


*Russia claims cover pancreatic cancer. Japan claims cover lung, breast, pancreas, head & neck, colon, prostate, liver, skin, brain, bone, kidney, ovarian, and uterine cancers.


About BioCurity Pharmaceuticals Inc. 

BioCurity's proprietary technology is designed to protect normal cells from radiation damage without impacting the effectiveness of radiation treatment. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development.  Visit BioCurity's website and follow them on LinkedIn and Facebook.


This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

Notice of Funds Disbursement

2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}